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Manuscript 
Abstract 
Rationale, aims and objectives: Timely switching from intravenous to oral therapy ensures 
optimised treatment and efficient use of healthcare resources. Intravenous (IV) paracetamol is 
widely used for postoperative pain management but not always switched to the oral form in a 
timely manner, leading to unnecessary increase in expenditure. This study aims to evaluate 
the impact of a multifaceted intervention to promote timely switching from the IV to oral 
form in the postoperative setting. 
Methods: An evidence-based prescribing protocol was designed and implemented by the 
clinical pharmacy team in a single district general hospital in Egypt. The protocol specified 
the criteria for appropriate prescribing of IV paracetamol. Physicians were provided with 
information and educational sessions prior to implementation. A prospective, quasi-
experimental study was undertaken to evaluate its impact on IV paracetamol utilisation and 
costs. Data on monthly utilisation and costs were recorded for 12 months before and after 
implementation (January 2012 to December 2013). Data were analysed using interrupted time 
series analysis.   
Results: Prior to implementation, in 2012, total spending on IV paracetamol was 674,154.00 
Egyptian Pounds (L.E.) ($236,68.00). There was a non-significant (p>0.05) downward trend 
in utilisation (-32 ampoules/month) and costs (reduction of 632 L.E. ($222)/month). 
Following implementation, immediate decrease in utilisation and costs (p<0.05) and a trend 
change over the follow-up period were observed. Average monthly reduction was 26% (95% 
CI: -24% to -28%, p <0.001).  
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Conclusion: A multifaceted, protocol-based intervention to ensure timely switching from IV-
to-oral paracetamol achieved significant reduction in utilisation and cost of IV paracetamol in 
the first five months of its implementation.   
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Introduction 
In the current health care spending landscape, where demand is increasing and resources are 
limited, it is essential that hospitals implement evidence-based policies for the utilisation of 
drugs[1]. The choice of the appropriate route of administration and dosage form is an 
important step in the prescribing of medicines to achieve optimised outcomes from the 
limited drugs’ budget [2,3]. Given the differential pricing of the medicines’ formulations, it is 
important that the choice between these is guided by evidence regarding cost-effectiveness. 
For example, in the context of operative and intensive care, the choice of the intravenous 
route when the oral route is possible or a nasogastric tube is being used would not be 
appropriate [4]. 
Hospitalised patients often begin to receive their medications intravenously when acutely ill 
or postoperatively. However, they are not usually switched to the oral medication in a timely 
manner (i.e. when they become stable and start taking oral medications or diet)[5]. Clinical 
guidelines on acute pain management in adults in the USA,France, the United Kingdom and 
Australia recommend oral administration of drugs as soon as patients can take them [6-9]. 
Hence, interventions have been developed and implemented to ensure timely switching from 
the intravenous to the oral route in the post-operative administration of drugs. For example, 
Colombet et al. implemented an intervention to promote early switching from IV to oral 
proton pump inhibitors (PPIs) following a sharp increase in the utilisation and associated 
costs of IV forms of PPIs. The intervention was successful in reducing the utilisation of IV 
PPIs, although in the long run this change was not sustainable [8]. Ripouteau et al. applied a 
multifaceted intervention to promote early switching from IV to oral administration of 
paracetamol for pain management [7]. The authors argued that patients, nurses and other 
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health care professionals erroneously believed that IV paracetamol was more effective and 
were not aware of the much higher costs associated with its use. 
Acetaminophen (paracetamol or N-acetyl-P-aminophenol [APAP]) is a well-known and 
approved medication for the management of mild to moderate perioperative pain alone; the 
management of moderate to severe pain with adjunctive opioid medication; and reduction of 
fever [11]. It has been suggested that, its mechanism of action is produced through central 
effect. The analgesic effect targets cyclooxygenase isoenzymes, endogenous opioid or 
serotoninergic bulbospina pathways and/or cannabinoid tone [12]. The antipyretic effect is 
mediated through inhibition of prostaglandin formation that otherwise acts to increase the 
temperature within the hypothalamus [13]. 
The safety, tolerability and non-sedating effect of paracetamol have been considered the main 
advantages of this medication, although how safe paracetamol is has been recently disputed 
[14]. It is available in the market as oral, rectal and IV preparations. The IV preparation (10 
mg/ml solution for infusion) has been available to the European market since 2002 and was 
introduced to the Egyptian market in 2006  following approval from the Egyptian Ministry of 
Health. In 2010 it was marketed in the USA. Oral paracetamol is a simple well-tolerated 
analgesic; but if meaningful early plasma concentrations are required, a more generous 
loading dose is needed [15].The IV form is successful in achieving rapid therapeutic 
concentrations that can subsequently be maintained by oral absorption [16,17]. There is a 
considerable difference between the price of the IV and the oral forms in the Egyptian 
market, with the oral form priced at 0.05 L.E. ($0.02) per 100 mg while the IV form priced at 
1.95 L.E. ($6.85) per 100 mg for the IV form. 
Oral dosage forms have several advantages compared to IV, including: lower cost, less 
administration time by nursing staff with lower risk of infection, and increased patient 
comfort and safety through eliminating the requirement for intravenous catheters [18]. Prior 
research in the setting of community-acquired pneumonia has demonstrated that an early IV-
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to- Per Oral (PO) switch of medications can also shorten the duration of hospitalisation 
[19,20]. 
In Egyptian hospitals the absence of electronic drug-ordering systems - which would enable a 
central computer to provide a daily list of all patients who are on IV paracetamol for long 
periods (and are therefore potential candidates for an IV-to-PO switch) - greatly reduces the 
number of patients who are switched in a timely manner. Given the large difference in price 
between oral and IV forms, this represents a considerable waste in a health system that is 
already struggling to provide basic health care due to its limited resources. 
Ripouteau and colleagues proposed the use of an educational intervention targeted at nurses 
and other health care professionals to promote early switching from IV to oral paracetamol 
which showed promising results. However the study was conducted in France in 2000 and its 
results would be of limited generalisability to Egyptian hospitals aiming to achieve this [7]. 
Hence, we developed a multifaceted, protocol-based intervention to increase the efficiency of 
postoperative pain management by identifying patients who are suitable candidates for IV-to-
PO switching and promptly implementing the switch. The aims of this pilot study were: to 
assess the impact of this multifaceted, protocol-based intervention on the utilisation and cost 
of IV paracetamol and to assess the feasibility of the protocol implementation and its 
acceptability among physicians, with the aim of generating evidence to inform national 
guideline development and implementation. In contrast to Ripouteau et al, our intervention 
was primarily restrictive and was implemented as a pharmacist-led initiative at a whole 
hospital level, rather than a single surgical department [7]. 
Methods 
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This is a prospective, quasi-experimental study; where data were collected before and after 
the implementation of this non-computerised protocol. The effect of this protocol on the 
utilisation and costs of IV paracetamol was assessed using interrupted time series analysis. 
1. Setting 
The intervention was implemented in a single district general hospital in the Egyptian capital, 
Cairo. The hospital, which has140 beds, is covered by 22 specialties. The average number of 
surgeries per month is around 400, performed by 17 of the 22 specialties. 
2. Standard procedures for pain management prior to the intervention: 
The standard procedure for postoperative pain management in the hospital was to use IV 
paracetamol immediately after surgery and to maintain it as long as the patient reported 
feeling pain or until discharge. Ideally, patients would then be switched to oral paracetamol 
when they are able to take oral medications. However, this was not usually done in a timely 
manner. 
3. Intervention design and implementation: 
The general approach was to develop, implement and assess the impact of the intervention. 
The drugs and therapeutics committee (DTC) oversaw the approval, development and 
implementation of the protocol. The process involved the following stages: 
3.1. Defining the criteria for IV paracetamol prescribing: 
In accordance with the nature of the hospital, a general hospital with multispecialty, it was 
necessary to tailor a list suitable to the nature of the hospital patients. This list was 
developed based on published guidelines [8,9] and specified that IV paracetamol can be 
prescribed: 
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o for surgical patients within 48 hours post-operatively; 
o for null-per-oral (NPO) patients or patients with mucositis suffering from pain; 
o for other pain patients only after the approval of the DTC chairman or the pain 
management team;  
o in acutely febrile patients (temperature > 38°C), where one single dose of IV 
paracetamol is recommended, followed by oral form if a regular regimen is 
required; and 
o to patient with erratic gastric absorptions. 
3.2. Designing the IV-to-PO switching protocol 
The main steps of the protocol are summarised in Figure 1 which illustrates the steps involved in 
the process. 
Figure 1: Flow chart illustrating the steps involved in the protocol-based process and 
the criteria for dispensing IV paracetamol 
3.3. Revision and approval of the protocol 
The protocol was presented to both the pain management team and the DTC for revision 
and approval to ensure local consensus and physician buy-in.  
3.4. Pharmacists training 
All the ward pharmacists in the hospital received written orientation about the inclusion 
criteria and on-the-job training on the implementation of the protocol. 
3.5. Physician orientation 
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A 10-minute session was designed to be delivered to the physicians. These sessions were 
delivered by the pharmacy team. Also, electronic messages (via E-mails and SMS) were sent 
to all the physicians via the hospital medical council to inform them about the new protocol 
and the date it was due to come into effect. 
3.6. Official implementation of the protocol 
The approved protocol was officially launched on the 1st of January 2013. From this date, 
all the medication sheets were screened by the ward pharmacists twice daily before 
dispensing doses (10 am dose and 10 pm dose) to ensure that the policy was being 
implemented. 
4. Data collection and analysis 
In order to assess the change in the utilisation of IV paracetamol, data on the number of IV 
ampoules consumed for the whole hospital were extracted from the hospital pharmacy 
records on a monthly basis over one year, from the 1st January 2013 to 31st December 2013. 
Data for the pre-implementation phase were also extracted from the hospital pharmacy’s 
dispensing records for an equivalent period of time directly preceding the implementation of 
the intervention (1st January 2012 to 31st December 2012). Further to reviewers’ comments, 
data on the consumption and costs of oral paracetamol were also obtained from the pharmacy 
records and analysed similarly. As the intervention was not targeted at individual patients and 
no patient identifiable data were collected, patient consent was not required.  
Costs of IV paracetamol were calculated by multiplying the number of dispensed ampoules 
by their unit cost (19.50 L.E. ($6.85). Similarly, the costs of oral paracetamol were calculated 
using its unit cost (0.05 L.E. ($0.02) per 100 mg). 
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Paired sample t-test was used to assess the significance of the change in monthly utilisation 
and costs before and after the intervention. Statistical significance was set at p < 0.05. The 
time series (12 points before and 12 points after the intervention implementation) was 
analysed using Interrupted Time Series (ITS) analysis. Autoregressive Integrated Moving 
Average (ARIMA) models were used to analyse associations between observations in the 
pre-intervention series [21,22]. The outcome of this analysis satisfied the assumptions of the 
general linear regression model; hence, a segmented regression model including time and 
intervention terms could be applied to the original time series.  
All the analysis was conducted using SPSS (v.16) software. Costs were calculated in 2012-
2013 Egyptian Pounds (L.E) and converted to US Dollars using the International Monetary 
Fund (IMF) Purchasing Power Parity (PPP) (using CCEMG – EPPI-Centre Cost Converter 
available at: http://eppi.ioe.ac.uk/costconversion/Default.aspx ) . 
Results 
Monthly and total annual inpatient utilisation and costs of IV paracetamol in the period from 
January 2012 to December 2013 and the change in monthly and annual costs are presented in 
Table 1.  
Table 1:  Total monthly IV paracetamol utilisation and associated costs over the study 
period (January 2012 to December 2013) 
Overall, the total annual utilisation of IV paracetamol was 34,572 ampoules in 2012, before 
the introduction of the intervention. The average monthly utilisation was 2,881 ampoules 
(95% CI: 2,807-2,955). This equates to a total cost of 674,154.00 L.E., with an average 
monthly cost of 56,180.00 L.E. (95% CI: 54,739.00 to 57,620.00 L.E.).  
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In 2013, following implementation, the total utilisation of IV paracetamol fell to 25,344 
ampoules with a monthly average of 2,111 (95% CI: 2068 to 2155). The total cost in 2013 
was 494,013.00 L.E. with a monthly average of 41,168.00 L.E. (95% CI: 40,317.00 to 
42,018.00 L.E.).  
Thus, the reduction in monthly utilisation compared to pre-intervention values ranged from 
329 to 1,234 ampoules with an average of 770 ampoules (95% CI: 677 to 830). This 
reduction was highly statistically significant (p < 0.001). The monthly saving achieved, 
Figure 2, ranged from 6,416.00 to 24,063.00 L.E., with an average monthly saving of 
15,012.00 L.E. (95% CI: 13,599.00 to 16,464.00 L.E., p < 0.001). These data showed that the 
relative reduction in monthly utilisation and costs ranged from 14% to 39% with an average 
of 26% (95% CI: 24% to 28%, p < 0.001).  
Using the Interrupted Time Series analysis, to adjust for the level of change observed in the 
pre-intervention period, it was estimated that before the intervention there was a downward 
trend with a decrease of 32 units per month; however, this was not statistically significant (p 
= 0.056) (Table 2). Similarly, there was an average decrease in monthly cost by 632 
L.E.($222), which was not statistically significant (p = 0.067) (Table 2). After the 
implementation of the intervention, in January 2013, there was an immediate change in the 
average monthly utilisation and costs and a trend change was observed over the whole follow 
up period.  
In the first month, upon the introduction of the intervention, there was a statistically 
significant reduction in utilisation (p = 0.001) and costs (p = 0.003) compared with the pre-
intervention period. The initial effect of the intervention decreased with time (months 1 to 5). 
After month 5, the reduction was still evident in absolute and relative terms but not 
significantly different in statistical terms from the pre-intervention period for both monthly 
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utilisation (p = 0.07) and costs (p = 0.071). This suggests that the intervention effect was 
sustained for the first 5 months of implementation but its effect was attenuated after this 
period. Figure 2 shows the time series for IV paracetamol utilisation before and after the 
implementation of the intervention.  
Table 2:  Summary of the AutoRegressive Integrated Moving Average (ARIMA) model 
analysis showing the estimated reduction in IV paracetamol utilisation and costs 
following intervention implementation compared with pre-intervention levels. 
Figure 2: Time series of monthly IV paracetamol utilisation before and after the 
implementation of the protocol-based intervention. 
The consumption of oral paracetamol and associated costs were significantly higher in 2013 
compared to 2012 (p=0.84, see Table 3). ARIMA analyses showed that there was an increase 
in the consumption of the oral form in the first months upon the introduction of the 
intervention, however, this increase was not statistically significant.  
Table 3: Total monthly oral paracetamol utilisation over the study period (January 
2012 to December 2013) 
To assess the net effect of the intervention, the total cost of both the oral and IV forms was 
also analysed. This has confirmed that there was a significant reduction in total paracetamol 
costs in the first 5 months of 2013 (p< 0.05), driven by the reduction in the consumption and 
cost of the more expensive IV form.  
The total number of admissions to the hospital was 10,682 in 2012 (before the introduction of 
the intervention) and 10,982 in 2013 (following the introduction of the intervention). The 
average monthly number of admissions was 890 (SD = 53) in 2012 and 915 (SD = 55) in 
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2013. The difference in the mean number of admissions between the two years was not 
statistically significant (p = 0.27). 
Discussion 
The results of this study showed that, a multifaceted, protocol-based intervention 
implemented at a general hospital achieved a significant reduction in the utilisation and cost 
of IV paracetamol. The effect was statistically significant, showing a significant discontinuity 
in the utilisation and costs of IV paracetamol immediately after its implementation and a 
sustained effect for the first 5 months. In absolute terms, this reduction continued over the 
study period. Adjusting for the pre-intervention trend showed that after 5 months the change 
in the rate of reduction in utilisation was not statistically significant compared with the pre-
intervention trend.  
Pain management in hospitalised patients is a necessary skill set for all physicians. Pain is so 
pervasive in the hospital setting that it is sometimes referred to as “the fifth vital sign,” and 
failure to manage pain has important implications not only for physicians, but also for the 
hospitals where they practice [23]. The World Health Organization (WHO) reports that the 
irrational use of medicines is a major problem worldwide [24]. The over-use of parenteral 
formulations, while oral formulations would be as appropriate, is one of the key factors 
contributing to the irrational use of medicines and unnecessary increase in drug spending 
[25]. IV-to-PO switching within an appropriate time postoperatively is one of the major areas 
that could be targeted to rationalise the use of parenteral forms [26].  Thus, the results of this 
study have relevance internationally to help ease the burden on already stretched resources.  
The cost of IV paracetamol is several times higher compared to the oral form (0.05 L.E. 
($0.02) per 100 mg for the oral vs 1.95 L.E. ($6.85) per 100 mg for the IV preparation), this 
would not stop physicians from prescribing the IV formulation in Egypt. However, adherence 
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to guidelines regarding early switching from IV to oral therapy in Egypt is still not 
appropriate. The lack of computerised prescribing systems is a major contributing factor to 
this low level of adherence [27]. However, this poor adherence is a problem also in other 
developed countries (e.g. the United Kingdom) [28]. 
In the context of postoperative pain management, the use of the IV route is clinically justified 
where there is an urgent need to treat pain and/or when other routes of administration are not 
possible [29]. However, the IV route may not always be used appropriately and can be 
associated with potential problems such as: associated risks of infection; local pain and 
inflammation; possible overdose with concomitant oral medicines containing paracetamol, 
especially in patients with hepatic impairment or severe renal impairment; failure to adjust 
the dose according to body weight or other patient-related factors. These issues may lead to a 
considerable increase in nursing time and costs [7,29].  Hence, the recommendation is to 
switch to the oral route as soon as this becomes possible. Adhering to this evidence-based 
prescribing practice has proven to be cost-effective; achieving positive outcomes in terms of 
reduced risk of infection and hospital length of stay while reducing the costs associated with 
IV paracetamol use [7]. The effect of such adherence was evident in this intervention study as 
well, where a significant reduction in utilisation and costs was achievable without adversely 
affecting the level of postoperative pain management, where patient-requested analgesics’ 
utilisation levels remained stable over the two-year study period. The utilisation of oral 
paracetamol increased in the first months upon the introduction of the intervention, however 
this increase was not statistically significant. The total cost of paracetamol (oral plus IV) 
showed a significant reduction in the first 5 months, driven by the reduction in the utilisation 
of more expensive IV form. 
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Previous studies that examined the effectiveness of interventions to promote IV- to Oral 
switching for paracetamol, PPIs and antibiotics have shown similar results, with an initially 
significant change in physicians’ prescribing behavior, which tended to level off [7,10,30,31]. 
A systematic review of the effectiveness of similar interventions to improve antibiotic 
prescribing in hospitals included studies of interventions directed to changing the route of 
administration [32]. The review concluded that restrictive interventions, such as automatic 
stop orders similar to the intervention used in this study, had a significantly greater impact on 
prescribing outcomes in the short-run (6 months) but not in the long-run (12 and 24 months) 
when compared to persuasive interventions [32]. This trend suggests that there may be a need 
for follow-up measures and continuous education to maintain the achieved change. However, 
overall, the average level of change seen in this study (26% reduction in utilisation of IV 
paracetamol) was found to be within the range reported in this Cochrane review when using 
primarily restrictive interventions (17% to 34% in the desired direction) [32]. It is also likely 
that the level of utilisation may have reached an optimum level, with no further room for 
improvement. 
The use of ITS analysis can be a particularly useful method in prescribing research to allow 
the analysis of drug prescribing and utilisation levels and trends. It can be a powerful tool for 
hospital pharmacies to track and identify challenging and non-evidence based prescribing 
practices that require remedial action. It has been used to assess the effectiveness of 
interventions to improve prescribing of various medications including antidepressants, 
antibiotics and proton pump inhibitors [10,33,34]. The implementation of a computer 
physician order entry (CPOE) system can further enhance the usability of this method and 
simplify the data collection. A CPOE system would also make it possible to design 
interventions based on sending computerised reminders to prescribers in addition to 
facilitating the collection of real-time data for audit and research purposes [18]. 
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There are a number of limitations to our study. Firstly, it was conducted at a single hospital in 
a large city and consequently the findings may not be generalisable to other settings. 
Secondly, the study focused on assessing changes in process measures on a whole hospital 
level rather than clinical outcomes on an individual patient level. Finally, the results may 
have been confounded by other factors such as the case mix; given the quasi-experimental 
before-and-after research design. Nevertheless, and despite these limitations, the study 
showed that this protocol-based intervention has achieved considerable efficiency saving in a 
resource-limited setting. Reinforcing the messages delivered through the implementation 
activities on a bi-annual basis can further improve the outcomes and ensure maintenance of a 
positive effect. Further research should focus on assessing patient-level, clinical outcomes as 
part of a full pharmacoeconomic evaluation to assess the cost effectiveness of this 
intervention.  
In conclusion, the implementation of a protocol-based intervention to achieve a timely switch 
from IV to oral paracetamol in the context of postoperative pain management achieved an 
immediate significant reduction in the utilisation and cost of IV paracetamol. However, as 
with other interventions aimed at changing prescribing behaviour, this effect may require 
additional measures to be sustainable. Choosing the appropriate administration route is an 
important step in the prescribing process that can optimise patient outcomes in a cost-
effective manner.  
Acknowledgement 
The authors would like to acknowledge Dr Barry Hounsome for his efforts in critically 
reviewing and proof-reading the manuscript. We are also indebted to the clinical pharmacy 
team and the inpatient pharmacy staff for their role in implementing the protocol. 
Author contributions 
16 
 
NS and AA were involved in the conception and design of the study and oversaw data 
collection. DD, NH and DB contributed to the design of the study and advised on data 
collection. DD and NH undertook the data analysis. DD drafted the manuscript. NS, AA, NH 
and DB provided comments and critically revised the manuscript. All authors approved the 
final manuscript.  
 
 
17 
 
References: 
1. Picton, C. and Wright, H. (2013) Medicines Optimisation: Helping patients to make 
the most of medicines. Good practice guidance for healthcare professionals in 
England. London, Royal Pharmaceutical Society of Great Britain (RPSGB). 
2. deVries, T., Henning, R., Hogerzeil, H., Fresle, D. (1995) Guide to good prescribing: 
A practical manual. Geneva, World Health Organization Action Programme on 
Essential Drugs. 
3. Larkin, M. (2001) Evidence-based prescribing made simple. Lancet, 357(9254), 448. 
4. Fenlon, S., Collyer, J., Giles, J., Bidd, H., Lees, M., Nicholson, J., Dulai, R., Hankins, 
M., Edelman, N. (2013) Oral vs intravenous acetaminophen for lower third molar 
extractions under general anaesthesia: is oral administration inferior? British Journal 
of Anaesthesia, 110(3), 432-437. Doi: 10.1093/bja/aes387 
5. Cunha, B. (2001) Intravenous to oral antibiotic switch therapy. Drugs Today (Barc), 
37(5), 311-319. 
6. Carr, D., Jacox, A., Chapman, C. (1992) Acute pain management in adults: operative 
procedures. Rockville, MD: Agency for Health Care Policy and Research, Public 
Health Service, US Department of Health and Human Services (Quick reference 
guide for clinicians No 1. AHCPR Publication No 92-0019.) 
7. Ripouteau, C., Conort, O., Lamas, J.P., Auleley, G.R., Hazebroucq, G., Durieux, P. 
(2000) Effect of multifaceted intervention promoting early switch from intravenous to 
oral acetaminophen for postoperative pain: controlled, prospective, before and after 
study. British Medical Journal, 321, 1460-1463. Doi: 
http://dx.doi.org/10.1136/bmj.321.7274.1460 
18 
 
8. Western Australian Therapeutic Advisory Group. (2012) Guidance for the use of 
intravenous paracetamol in WA public hospitals, WA.TAG advisory note. 
http://www.watag.org.au/watag/docs/IV_paracetamol_Advisory_Note_26Nov12.pdf. 
(accessed 26 August 2015) 
9.  The Royal Bournemouth and Christchurch Hospital, NHS Foundation Trust. (2012) 
Guideline for paracetamol use. 
http://www.dorsetccg.nhs.uk/Downloads/aboutus/medicines-
management/Other%20Guidelines/Guideline%20for%20paracetamol%20use%20RB
CH.pdf. (accessed 26 August 2015) 
10. Colombet, I., Sabatier, B., Gillaizeau, F., Prognon, P., Begue, D., Durieux, P. (2009) 
Long-term effects of a multifaceted intervention to encourage the choice of the oral 
route for proton pump inhibitors: an interrupted time-series analysis. Quality and 
Safety in Health Care, 18, 232–235. Doi:10.1136/qshc.2007.023887 
11. Pasero, C., Stannard, D. (2012) The role of intravenous acetaminophen in acute pain 
management: a case-illustrated review. Pain Management Nursing, 13(2),107-24. 
12. Mattia, A., Coluzzi, F. (2009) What anesthiologists should know about paracetamol 
(acetaminophen). Minerva Anestesiology, 75(11), 644-653.  
13. Graham, G., Scott, K. (2005) Mechanism of action of paracteamol. American  Journal 
of  Therapeutics, 12(1), 46-55. 
14. Joshi, G.P. (2005) Multimodal analgesia techniques and postoperative rehabilitation. 
Anesthesiology Clinics of North America, 23(1), 185-202. 
Doi:10.1016/j.atc.2004.11.010 
15. Holmer-Pettersson, P., Owall, A., Jakobsson, J. (2004) Early bioavailability of 
paracetamol after oral or intravenous administration. Acta Anaesthesiologica 
Scandinavica, 48, 867-70. DOI: 10.1111/j.0001-5172.2004.00452.x 
19 
 
16. Macario, A. and Royal, MA. (2011) A literature review of randomized clinical trials 
of intravenous acetaminophen (paracetamol) for acute postoperative pain. Pain 
Practice, 11, 290–610. Doi: 10.1111/j.1533-2500.2010.00426.x. 
17. Moller, P., Sindet-Pedersen, S., Petersen, C.T., Juhl, G.I., Dillenschneider, A., 
Skoglund, L.A. (2004) Onset of acetaminophen analgesia: Comparison of oral and 
intravenous routes after third molar surgery. British Journal of Anesthesia; 94, 642-
648. Doi: 10.1093/bja/aei109 
18. Fischer, M., Solomon, D., Teich, J., Avorn, J. (2003) Conversion from intravenous to 
oral medications: Assessment of a computerized intervention for hospitalized patients. 
Archives of Internal Medicine, 163(21), 2585-2589. 
Doi:10.1001/archinte.163.21.2585. 
19. Ramirez, J., Vargas, S., Ritter, G.W.,  Brier, M.E., Wright, A., Smith, S., Newman, 
D., Burke, J., Mushtaq, M., Huang, A. (1999) Early switch from intravenous to oral 
antibiotics and early hospital discharge. Archives of Internal Medicine, 159, 2449-
 2454. doi:10.1001/archinte.159.20.2449 
20. Oosterheert, J.J., Bonten, M.J., Schneider, M.M. et al.  (2006) Effectiveness of early 
switch from intravenous to oral antibiotics in severe community acquired pneumonia: 
multicentre randomised trial. British Medical Journal, 333, 1193-1205. Doi: 
http://dx.doi.org/10.1136/bmj.38993.560984.BE 
21. Box, G.E.P., Jenkins, G.M. (1976) Time series analysis, forecasting and control. San 
Francisco: Holden Day. 
22. Greene, W.H. (2002) Econometric analysis. 5th ed. Englewood Cliffs: Prentice-Hall. 
23. Harrington, D. (2013) IV Acetaminophen: The Hospitalist’s Perspective. Today’s 
Hospitalist Special Report. 
20 
 
http://www.todayshospitalist.com/index.php?b=articles_read&cnt=1637. (accessed 14 
June 2015) 
24. World Health Organization (WHO). (2012) The pursuit of responsible use of 
medicines: Sharing and learning from country experiences. 
http://www.who.int/medicines/publications/responsible_use/en/ (accessed 14 June 
2015) 
25. Lau, B., Pinto, B., Thiemann, D., Lehmann, C. (2011) Budget impact analysis of 
conversion from intravenous to oral medication when clinically eligible for oral 
intake. Clinical Therapeutics, 33(11), 1792 –1796. 
Doi:10.1016/j.clinthera.2011.09.030 
26. Cyriac, J. and James, E. (2014) Switch over from intravenous to oral therapy: A 
concise overview. Journal of Pharmacology and Pharmacotherapy, 5(2), 83-87. DOI: 
http://dx.doi.org/10.4103/0976-500X.130042 
27. O’Neal, J. (2013) The utility of intravenous acetaminophen in the perioperative 
period. Frontiers in Public Health, 1, 25. Doi:  10.3389/fpubh.2013.00025 
28. Marsden, M. (2010) Auditing use of IV paracetamol in a surgical division and 
intensive care. Clinical Pharmacist, 2, 225-228. 
29. Tzortzopoulou, A., McNicol, E.D., Cepeda, M.S., Francia, M.B.D, Farhat, T., 
Schumann, R. (2011) Single doses of intravenous formulations of paracetamol 
(acetaminophen) to reduce pain after surgery in adults and children. Cochrane 
Database of Systematic Reviews, 10. DOI: 10.1002/14651858.CD007126.pub2 
30. Rhew, D.C., Tu, G.S., Ofman, J., Henning, J.M., Richards, M.S., Weingarten, S.R. 
(2001) Early switch and early discharge strategies in patients with community- 
acquired pneumonia: a meta-analysis. Archives in Internal Medicine, 161(5),722-727. 
doi:10.1001/archinte.161.5.722 
21 
 
31. McLaughlin, C.M., Bodasing, N., Boyter, A.C., Fenelon, C., Fox, J.G., Seaton, R.A. 
(2005) Pharmacy-implemented guidelines on switching from intravenous to oral 
antibiotics: an intervention study. Quarterly Journal of Medicine, 98 (10), 745–52. 
DOI: http://dx.doi.org/10.1093/qjmed/hci114 
32. Davey, P., Brown, F., Fenelon, L. et al. (2013) Interventions to improve antibiotic 
practices for hospital inpatients. Cochrane Database of Systematic Reviews, 4. DOI: 
10.1002/14651858.CD003543.pub2 
33. Hanbury, A., Farley, K., Carl, Thompson., Wilson, P., Chambers, D., Holmes, H. 
(2013) Immediate versus sustained effects: interrupted time series analysis of a 
tailored intervention. Implementation Science, 8,130. Doi:10.1186/1748-5908-8-130 
34. Ansari, F., Gray, K., Nathwani, D., Phillips, G., Ogston, S., Ramsay, C., Davey, P. 
(2003) Outcomes of an intervention to improve hospital antibiotic prescribing: 
interrupted time series with segmented regression analysis. Journal of Antimicrobial 
Chemotherapy, 52, 842–848. Doi: 10.1093/jac/dkg459 
22 
 
Figure legends: 
 
Figure 1: Flow chart illustrating the steps involved in the protocol-based process and the 
criteria for dispensing IV paracetamol 
 
 
Figure 2: Time series of monthly IV paracetamol utilisation before and after the 
implementation of the protocol-based intervention. 
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Tables 
Table 1: Total monthly IV paracetamol utilisation and associated costs over the study 
period (January 2012 to December 2013) 
Month Units (1000 mg single use 
ampoule) 
Costs (L.E.)* 
2012 2013 2012 (a) 2013 (b) Difference in cost 
(b-a) 
January  2996 2045 58,422 39,878 -18,544 
February  2605 1994 50,798 38,883 -11,915 
March  3073 2149 59,924 41,906 -18,018 
April  3067 2128 59,807 41,496 -18,311 
May  2986 2005 58,227 39,098 -19,129 
June  3248 2305 63,336 44,948 -18,388 
July  3152 1918 61,464 37,401 -24,063 
August 2752 2301 53,664 44,870 -8,794 
September 2925 2345 57,038 45,728 -11,310 
October 2428 2099 47,346 40,931 -6,415 
November 2839 2179 55,361 42,491 -12,870 
December 2501 1866 48,770 36,387 -12,383 
Total 34572 25344 674,154 494,013 -180,141 
* IV paracetamol unit cost = 19.5 L.E. 
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Table 2: Summary of the AutoRegressive Integrated Moving Average (ARIMA) model 
analysis showing the estimated reduction in IV paracetamol utilisation and costs 
following intervention implementation compared with pre-intervention levels. 
Time after 
introducing 
intervention 
(months) 
Change in utilisation (units) Change in cost (L.E.) 
Mean  
(95% CI) 
P-value 
Mean  
(95% CI) 
P-value 
0 (pre-intervention) 
-32 (-66, 2) 0.056 -6,32(-1,342, 78) 0.067 
1 
-636 (-985, -287) 0.001* -11,418 (-18,575, -4,261) 0.003* 
2 
-585(-938, -233) 0.002* -10,695 (-1,7966, -3,424 0.005* 
3 
-534 (-897, -171) 0.005* -9,972 (-1,7489, -2,455) 0.009* 
4 
-484 (-864, -103) 0.013* -9,248 (-17,127, -1,369) 0.019* 
5 
-433 (-836, -29) 0.031* -8,525 (-16,870, -180)         0.038* 
6 
-382 (-813, 49) 0.070 -7,802 (-16,700, 1,096)  0.071 
7 
-331(-794, 132) 0.137 -7,079 (-16,603, 2,445) 0.122 
8 
-280 (-778, 218) 0.237 -6,355 (-16,561, 3,851) 0.191 
9 
-229(-765, 307) 0.364 -5,632 (-16,570, 5,306) 0.276 
10 
-178 (-754, 398) 0.509 -4,909 (-16,616, 6,798) 0.372 
11 
-127 (-744, 490) 0.659 -4,186 (-16,695, 8,323) 0.475 
12 
-76(-736, 584) 0.804 -3,463 (-16,802, 9,876)  0.578 
*Statistically significant (P < 0.05) 
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Table 3: Total monthly oral paracetamol utilisation over the study period (January 
2012 to December 2013) 
Month 2012 (a) 2013 (b) Change in utilisation 
(b-a) 
Change in costs 
(L.E)* 
January  3901 6222 2321 580 
February  3797 6193 2396 599 
March  3950 5226 1276 319 
April  3449 3680 231 58 
May  4312 4261 -51 -13 
June  3007 3991 984 246 
July  3475 2763 -712 -178 
August 2459 2875 416 104 
September 3499 4135 636 159 
October 3547 3593 46 12 
November 4250 3856 -394 -99 
December 4737 4025 -712 -178 
Total 44383 50820 6437 1,609 
*calculated using unit cost of 0.25 L.E/500 mg.  
 
 
